
The Sildenafil/Tadalafil Blend Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of sildenafil and tadalafil in combined oral dosage forms.
The analysis is suitable for pills, tablets, and capsules containing both compounds, with individual results reported in milligrams per tablet or capsule.
Sildenafil and tadalafil are orally active phosphodiesterase type 5 (PDE5) inhibitors. Both compounds inhibit PDE5 and support the nitric oxide–cGMP signalling pathway involved in smooth muscle relaxation and increased blood flow.
Although they belong to the same pharmacological class, sildenafil and tadalafil differ in their pharmacokinetic profiles and duration of action. This analysis is specifically designed for products containing both compounds in a single formulation.
Important Notice
- This analysis is specifically intended for products containing sildenafil and tadalafil. It does not automatically screen the sample for other PDE5 inhibitors, related compounds, contaminants, or undeclared substances.
- The minimum amount of each target compound required for evaluation is 2 mg. Samples containing lower amounts may not be reliably evaluated within the standard scope of the analysis.
The following optional laboratory services are available:
